Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $67 from $72 on lowered estimates, while reiterating an Outperform rating on the stock. The analyst recently surveyed high-volume U.S. endocrinologists on the latest in continuous glucose monitoring now with Abbott's (ABT) Libre Flash on the market. According to respondents, there is some impact on Dexcom new prescriptions since Libre launch and some current Dexcom patients are interested in switching, but the impact looks within expectations, he contends. Overall, Lichtman believes the rollouts of Libre and Medtronic's (MDT) 670G remain overhangs on Dexcom near-term, but his survey suggests an environment no worse than guidance and conditions on the ground should change again in 2H18 with approval of Dexcom's next-generation G6.